Cases & Deals

  • Home
  • Practices
  • BioMarin pursues litigation against Ascendis Pharma A/S in UPC

Share

BioMarin pursues litigation against Ascendis Pharma A/S in UPC

January 2025

Client(s) BioMarin Pharmaceutical Inc.

Jones Day represents BioMarin Pharmaceutical, Inc. in patent infringement proceedings against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide ("CNP").

BioMarin v. Ascendis, UPC CFI 18/2025

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.